系统性硬化症患者的间歇性肺病:我们可以从SENSCIS试验中学到什么?
Shervin Assassi1, Sudhakar Tumuluri2, Robert W Levin3
1Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, USA. shervin.assassi@uth.tmc.edu.
在SENSCIS试验中发现,nintedanib减缓了系统性硬化症相关的间歇性肺病 (SSc-ILD) 的肺功能下降. 这种治疗在患者群体中显示出一致的益处,尽管主要是胃肠道副作用.
科学领域:
- 肺部病理学 肺部病理学
- 类风湿病学 类风湿病学
- 临床试验 临床试验
背景情况:
- 系统性硬化症相关的间歇性肺病 (SSc-ILD) 是一种具有显著发病率的渐进性疾病.
- 该SENSCIS试验是迄今为止调查SSc-ILD治疗方法的最大研究.
- 早期识别和干预对于管理SSc-ILD进展至关重要.
研究的目的:
- 在SSc-ILD患者中,与安慰剂相比,评估宁泰达尼布的疗效和安全性.
- 评估宁泰达尼布对SSc-ILD患者肺功能下降的速度的影响.
- 探索疾病进展和治疗反应的潜在预测因素.
主要方法:
- 一个大规模的,随机的,安慰剂对照试验 (SENSCIS) 涉及576名SSc-ILD.患者.
- 在高分辨率计算机断层扫描 (HRCT) 上,患者的纤维化间歇性肺病 (ILD) 程度>10%.
- 强迫性生命能力 (FVC) 在52周内下降是主要的疗效终点.
主要成果:
- 与安慰剂相比,丁丁达尼布在52周内显著降低了FVC下降率.
- 任泰达尼布的治疗效果在各种子组中一致,包括抗毒素酶I抗体 (ATA) 状态和疾病亚型 (dcSSc vs. lcSSc).
- 副作用主要是胃肠道,腹是最常见的; 尼丁达尼布没有显著影响皮肤纤维化或生活质量.
结论:
- 在SSc-ILD患者中,丁丁达尼布在减缓肺功能下降方面表现出有效性.
- 这项SENSCIS试验的结果支持nintedanib作为SSc-ILD的有价值的治疗选择.
- 建议在管理SSc-ILD时及时诊断和启动治疗,例如用nintedanib.
更多相关视频
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
相关概念视频
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Nephrotic Syndrome II : Assessment and Medical Management
Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
